Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.

Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin.
复制标题

DOI:
10.1111/j.1600-6143.2011.03826.x
复制
发表时间:
2012-02
期刊:
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
影响因子:
--
通讯作者:
Wolf M
Wolf M
中科院分区:
其他
文献类型:
--
作者:
Cortazar F;Molnar MZ;Isakova T;Czira ME;Kovesdy CP;Roth D;Mucsi I;Wolf M

文献摘要

参考文献

被引文献

相似文献

Inhibitors of the mammalian target of rapamycin (mTOR), sirolimus and everolimus, reduce the incidence of acute rejection following kidney transplantation but their impact on clinical outcomes beyond two years after transplantation is unknown. We examined risks of mortality and allograft loss in a prospective observational study of 993 prevalent kidney transplant recipients who enrolled a median of 72 months after transplantation. During a median follow-up of 37 months, 87 patients died and 102 suffered allograft loss. In the overall population, use of mTOR inhibitors at enrollment was not associated with altered risk of allograft loss, and their association with increased mortality was of borderline significance. However, history of malignancy was the strongest predictor of both mortality and therapy with an mTOR inhibitor. Among patients without a history of malignancy, use of mTOR inhibitors was associated with significantly increased risk of mortality in propensity score-adjusted (hazard ratio [HR] 2.6; 95%CI, 1.2, 5.5; P = 0.01), multivariable-adjusted (HR 3.2; 95%CI, 1.5, 6.5; P = 0.002) and one-to-one propensity score-matched analyses (HR 5.6; 95% CI 1.2, 25.7; P = 0.03). Additional studies are needed to examine the long-term safety of mTOR inhibitors in kidney transplantation, especially among recipients without a history of malignancy.
DOI: 10.1046/j.1523-1755.2000.00816.x
发表时间: 2000-01-01
影响因子: 19.6
作者:
Ojo, AO;Hanson, JA;Port, FK
通讯作者: Port, FK
DOI: 10.1097/01.tp.0000184006.43152.8d
发表时间: 2005-10-15
期刊: TRANSPLANTATION
影响因子: 6.2
作者:
Kauffman, HM;Cherikh, WS;Kahan, BD
通讯作者: Kahan, BD
DOI: 10.1056/nejmoa067411
发表时间: 2007-12-20
影响因子: 158.5
作者:
Ekberg, Henrik;Tedesco-Silva, Helio;Halloran, Philip F.
通讯作者: Halloran, Philip F.
DOI: 10.1056/nejm200006223422506
发表时间: 2000-06-22
影响因子: 158.5
作者:
Benson, K;Hartz, AJ
通讯作者: Hartz, AJ
DOI: 10.1056/nejmoa012843
发表时间: 2002-06-06
影响因子: 158.5
作者:
Morice, M;Serruys, PW;Falotico, R
通讯作者: Falotico, R